Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M202291200 on May 13, 2002

J. Biol. Chem., Vol. 277, Issue 29, 26233-26237, July 19, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/29/26233    most recent
M202291200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zawalich, W. S.
Right arrow Articles by Zawalich, K. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zawalich, W. S.
Right arrow Articles by Zawalich, K. C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Effects of Glucose, Exogenous Insulin, and Carbachol on C-peptide and Insulin Secretion from Isolated Perifused Rat Islets*

Walter S. ZawalichDagger and Kathleen C. Zawalich

From the Yale University School of Nursing, New Haven, Connecticut 06536-0740

Received for publication, March 8, 2002, and in revised form, May 7, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Isolated perifused rat islets were stimulated with glucose, exogenous insulin, or carbachol. C-peptide and, where possible, insulin secretory rates were measured. Glucose (8-10 mM) induced dose-dependent and kinetically similar patterns of C-peptide and insulin secretion. The addition of 100 nM bovine insulin had no effect on C-peptide release in response to 8-10 mM glucose stimulation. The addition of 100 nM bovine insulin or 500 nM human insulin together with 3 mM glucose had no stimulatory effect on C-peptide secretion rates from perifused rat islets. Stimulation with carbachol plus 7 mM glucose enhanced both C-peptide and insulin secretion, and the further addition of 100 nM bovine insulin had no inhibitory effect on C-peptide secretory rates under this condition. Perifusion studies using pharmacologic inhibitors (genistein and wortmannin) of the kinases thought to be involved in insulin signaling potentiated 10 mM glucose-induced secretion. The results support the following conclusions. 1) C-peptide release rates accurately reflect insulin secretion rates from collagenase-isolated, perifused rat islets. 2) Exogenously added bovine insulin exerts no inhibitory effect on release to several agonists including glucose. 3) In the presence of 3 mM glucose, exogenously added bovine or human insulin do not stimulate endogenous insulin secretion.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Insulin secretion from the pancreatic beta -cell is tightly regulated by stimulatory signals generated during the intracellular metabolism of glucose and by neurohumoral agonists operative at the cell membrane (1-5). Most recently an additional layer of complexity has been added by reports suggesting that insulin exerts an autocrine stimulatory effect on insulin secretion from the beta -cell (6, 7). This concept was based primarily on amperometric measurements using beta -cells preincubated in 5-hydroxytryptamine (5HT).1 Because 5HT exposure exerts inhibitory effects on insulin release (8-10), the precise physiologic significance of findings made with 5HT-preloaded beta -cells is unclear. Moreover, previous studies exploring the potential role of insulin on stimulated secretion showed no effect (11) or supported the concept that insulin exerts a negative, not positive, feedback on its own secretion (12-15).

There are at least three major issues that must be addressed in attempting to establish the impact of exogenously added insulin on endogenous insulin secretory rates. The first is technical; it is difficult to accurately measure endogenous insulin release rates in the presence of exogenous insulin. The second relates to concentration of insulin necessary to establish an effect of exogenously added hormone on the beta -cell. Considering that the beta -cell continually releases insulin into a small volume of interstitial fluid, the level of insulin bathing the beta -cell may be quite high. For example, calculations based on islet cell volume, the insulin diffusion constant and insulin secretory rates, suggest that these levels may exceed 100 nM during glucose stimulation (16). Even at rest, levels of insulin far in excess of circulating plasma levels must exist at the interface of the beta -cell membrane and the interstitium. Third, the contribution of constitutive insulin release to the secretory responses observed has to be considered. The necessary insulin signaling components identified in insulin-sensitive tissues including insulin receptors, insulin receptor substrate proteins, and phosphatidylinositol 3-kinase have been found in beta -cells (17-19). Because there is constitutive secretion of insulin, a tonic level of insulin signaling in these cells may influence acute stimulatory responses and thus obscure any effect of exogenously added insulin. These three issues, in addition to the use of different species and disparate methodological approaches, may account in part for the discrepancies regarding the impact of insulin on its own secretion (11, 12, 14, 20, 21). To circumvent the first problem, and to establish the effect of exogenously added insulin on its own secretion, we have measured connecting (C)-peptide secretion rates in response to a variety of agonists from isolated perifused rat islets. Finally, the impact of insulin signaling on 10 mM glucose-induced secretion was explored using several compounds known to antagonize the kinases activated by insulin.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Islet Isolation-- The detailed methodologies employed to assess insulin output from collagenase-isolated rat islets have been described previously (22, 23). Male Sprague-Dawley rats (350-475g) were purchased from Charles River Laboratories, Inc. (Wilmington, MA). All animals were treated in a manner that complied with the National Institutes of Health (NIH) Guidelines for the Care and Use of Laboratory Animals (NIH publication no. 85-23, revised 1985). The animals were fed ad libitum. After intraperitoneal Nembutal (pentobarbital sodium, 50 mg/kg; Abbott Laboratories, Abbott Park, IL)-induced anesthesia, islets were isolated by collagenase digestion and handpicked, using a glass loop pipette, under a stereomicroscope. They were free of exocrine contamination.

Perifusion Studies-- Groups of 14-18 freshly isolated islets were perifused with Krebs-Ringer bicarbonate at a flow rate of 1 ml/min for 30 or 45 min with 3 mM glucose to establish basal and stable insulin and C-peptide secretory rates. After this stabilization period they were then perifused with the appropriate agonist or agonist combinations as indicated in the figure legends and under "Results." Perifusate solutions were gassed with 95% O2/5% CO2 and maintained at 37 °C. Insulin (24) and rat C-peptide released into the medium were measured by radioimmunoassay; in the case of C-peptide measurements the protocol provided by the vendor was followed rigorously. C-peptide and, when possible, insulin release rates were measured in the same perifusate samples.

Studies with Cultured Islets-- Groups of 14-18 islets were cultured as described previously (25, 26) for 18 h in CMRL-1066 containing 5.5 mM glucose and supplemented with penicillin (50 units/ml), streptomycin (50 µg/ml) and glutamine to achieve a final concentration of 2 mM. After this, the islets were perifused as described above.

Reagents-- Hanks' solution was used for the islet isolation. The Krebs-Ringer bicarbonate perifusion medium consisted of 115 mM NaCl, 5 mM KCl, 2.2 mM CaCl2, 1 mM MgCl2, 24 mM NaHCO3, and 0.17 g/dl bovine serum albumin. The 125I-labeled insulin used for the insulin assay was purchased from PerkinElmer Life Sciences. Bovine serum albumin (RIA grade), glucose, carbachol, wortmannin, genistein, glutamine, phorbol 12-myristate 13-acetate (PMA), bovine insulin (Cat. no. I5500), human recombinant insulin, and the salts used to make the Hanks' solution and perifusion medium were purchased from Sigma. Genistein and wortmannin were dissolved in Me2SO, and equivalent amounts of diluent were used in control studies. Rat insulin standard (lot 615-ZS-157) was the generous gift of Dr. Gerald Gold, Eli Lilly (Indianapolis, IN). CMRL-1066 and the antibiotics employed for the culture studies were purchased from Invitrogen. Collagenase (Type P) was obtained from Roche Molecular Biochemicals. Rat C-peptide was measured using kits purchased from Linco Research, St. Charles, MO.

Statistics-- Statistical significance was determined using the Student's t test for unpaired data or analysis of variance in conjunction with the Newman-Keuls test for unpaired data. A p value <= 0.05 was taken as significant. Values presented in the figure legends and under "Results" represent means ± S.E. of at least three observations.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Glucose-induced Insulin and C-peptide Secretion-- In the initial series of experiments isolated perifused rat islets were stimulated with 10 mM glucose. Insulin and C-peptide secretory rates were measured in the same perifusate samples. As shown in Fig. 1, islet responses to 10 mM glucose (in terms of peptide secretory rates) were kinetically and quantitatively very similar. Both the C-peptide and insulin responses were biphasic in nature and, when compared with prestimulatory release rates measured in the presence of 3 mM glucose, the addition of 10 mM glucose resulted in ~15-fold increments in the output of both peptides. Similar, although amplified, C-peptide and insulin responses were obtained when the perifusate glucose level was increased to 15 mM (results not shown).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 1.   Effects of 10 mM glucose stimulation on C-peptide and insulin secretion. Groups (n = 4) of 14-18 islets were perifused for 45 min with 3 mM glucose (G3) to establish basal and stable rates of peptide secretion. They were then stimulated for 45 min with 10 mM glucose (G10) for 30 min, and perifusate samples were analyzed for C-peptide (closed circles) and insulin (open circles). Mean values ± S.E. are depicted in this and all subsequent figures. This and subsequent figures have not been corrected for the dead space in the perifusion apparatus, ~2.5 ml or 2.5 min with a flow rate of 1 ml/min.

Effects of Exogenous Insulin on Glucose-induced C-peptide Secretion-- In the next experiment, islets were stimulated with 8 mM glucose, a level of the hexose that resulted in a modest 4-5-fold increase in insulin secretory rates (Fig. 2). For example, in the presence of 3 mM glucose islets released 30-35 pg of insulin/islet/min. After 40 min of stimulation with 8 mM glucose, the secretory rate increased to 143 ± 17 (n = 5) pg/islet/min. A similar response in terms of C-peptide secretion was also observed. Prestimulatory secretion rates (5-6 pg/islet/min) increased to 31 ± 5 pg/islet/min. To assess the potential impact of exogenous insulin on glucose-induced secretion, additional groups of islets were stimulated with 8 mM glucose plus 100 nM bovine insulin. The addition of exogenous insulin precluded the measurement of endogenous insulin secretion. However, using C-peptide secretion rates as an index of the endogenous insulin secretory response, no effect of added bovine insulin on C-peptide secretory rates was seen. 40 min after the onset of 8 mM glucose stimulation, C-peptide secretory rates averaged 32 ± 3 pg/islet/min in the presence of 100 nM bovine insulin.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   Effects of 8 mM glucose (G8) and exogenous insulin on C-peptide secretion rates from isolated perifused islets. Groups (n = 5) of 14-18 islets were perifused for 45 min with 3 mM glucose (G3) to establish basal and stable rates of peptide secretion. They were then stimulated for 40 min with 8 mM glucose (closed circles, solid line) or 8 mM glucose plus 100 nM bovine insulin (closed circles, dashed line) for 40 min, and perifusate samples were analyzed for C-peptide. Also depicted are the insulin secretory responses to 8 mM glucose alone (open circles).

Although not shown, we could detect no inhibitory effect of 100 nM bovine insulin on C-peptide responses to 7 or 10 mM glucose, levels of the hexose that increase endogenous insulin secretion about 2- or 10-15-fold, respectively, above those observed with 3 mM glucose.

Effects of Exogenous Insulin on Insulin Secretion-- It has been reported that 100 nM exogenous bovine insulin in the presence of 3 mM glucose increases insulin secretion from beta -cells, a response monitored not by the release of insulin but by 5HT release from 5HT-prelabeled beta -cells (6). We directly tested this concept in perifused islets, which retain a level of physiologic sensitivity to glucose stimulation comparable with that observed with the perfused rat pancreas preparation (27-29). After a 45-min stabilization period in the presence of 3 mM glucose, islets were perifused with 100 nM bovine insulin or 500 nM human insulin in the continued presence of 3 mM glucose. There was no stimulatory effect of either insulin preparation on C-peptide secretion rates (Fig. 3). Throughout the perifusion, basal and stable rates of C-peptide secretion were noted.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   C-peptide secretion rates of rat islets perifused with exogenous insulin. Groups of 14-18 islets were perifused with 3 mM glucose (G3) for 30 min to establish stable C-peptide secretion rates and then stimulated with 100 nM bovine insulin (closed circles, n = 4) or 500 nM human recombinant insulin (open triangles, n = 3) for 30 min in the continued presence of 3 mM glucose.

Carbachol-induced C-peptide and Insulin Secretion-- We considered that the process of collagenase isolating islets may disrupt beta -cell membrane integrity and that the lack of any effect of insulin on C-peptide secretion may be a consequence of this potential adverse effect of the isolation procedure. To address this concern, two sets of additional experiments were conducted. In the first set of experiments (Fig. 4) islets were stimulated with 7 mM glucose plus 5 µM carbachol, a cholinergic agonist that activates phospholipase C via a membrane muscarinic receptor (30-32). Islets stimulated with 7 mM glucose plus 5 µM carbachol responded with an approximate 4-fold increase in both insulin and C-peptide secretion rates. The response to this agonist combination was ~2.5-fold greater than the response to 7 mM glucose alone (results not shown). For example, 20, 30 or 40 min after the onset of stimulation with 7 mM glucose alone insulin release rates averaged 53 ± 9, 57 ± 10, or 58 ± 12 pg/islet/min (n = 8), respectively. The addition of carbachol increased the values at these times to 109 ± 29, 125 ± 18, or 126 ± 19 pg/islet/min (n = 5), respectively. The further addition of 100 nM insulin had no effect on C-peptide secretion to glucose plus carbachol stimulation (Fig. 4).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of 7 mM glucose (G7) plus 5 µM carbachol on C-peptide and insulin secretion rates. Groups of 14-18 islets were perifused for 45 min with 3 mM glucose to establish basal and stable rates of peptide secretion. They were then stimulated with 7 mM glucose plus 5 µM carbachol plus (n = 3) or minus (n = 5) the further addition of 100 nM bovine insulin. Insulin release rates (open circles), and C-peptide secretion rates (closed circles, solid line, no added bovine insulin; closed circles, dashed line, 100 nM bovine insulin added together with 7 mM glucose plus 5 µM carbachol).

In the next set of experiments, islets were first cultured for 18 h to allow more complete recovery of any potential adverse impact of the collagenase isolation procedure. Islets were then perifused with 3 mM glucose to establish basal C-peptide secretion rates prior to stimulation with 500 nM human insulin. Similar to the observations made with freshly isolated islets, the addition of human insulin was without any stimulatory effect on C-peptide secretion rates. Because culturing impairs islet sensitivity to glucose stimulation alone (25, 33, 34), these islets were then stimulated with the combination of 20 mM glucose plus 500 nM PMA (Fig. 5). This agonist combination resulted in an ~25-fold increase in C-peptide secretion rates from both control and prior insulin-stimulated islets.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 5.   C-peptide secretion rates from cultured islets. Groups of islets were isolated and then cultured for 18 h. One group (open circles, n = 4) was perifused for 90 min with 3 mM prior to stimulation with 20 mM glucose plus 500 nM PMA for 20 min. Only the final 25 min of this perifusion is shown. The second group (closed circles, n = 3) was perifused for 30 min with 3 mM glucose, 30 min with 3 mM glucose plus 500 nM human insulin, 30 min with 3 mM glucose, and 20 min with 20 mM glucose plus 500 nM PMA.

Effects of Genistein and Wortmannin on Glucose-induced Release-- In an attempt to disrupt the contribution of constitutive insulin signaling on glucose-stimulated beta -cell responses of our perifused islet preparation, additional studies were conducted with the tyrosine kinase inhibitor genistein (10 µM) and the phosphatidylinositol 3-kinase inhibitor wortmannin (50 nM). Both types of kinases are established participants in insulin signaling (35, 36). As shown in Fig. 6, both inhibitors significantly potentiated 10 mM glucose-induced secretion.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of genistein and wortmannin on glucose-induced insulin secretion. Groups of 14-18 islets were perifused with 3 mM glucose (G3) for 30 min. Islets were then stimulated (indicated by the vertical line) with 10 mM glucose alone (open circles), 10 mM glucose plus 10 µM genistein (closed circles, dashed line), or 10 mM glucose plus 50 nM wortmannin (closed triangles). The asterisk indicates a significant difference between the G10 controls and the G10 plus wortmannin- or genistein-treated islets at this time point.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Several important considerations have emerged in our attempt to establish the precise impact of exogenously added insulin on endogenous insulin secretory rates. First is the realization that the levels of insulin bathing the beta -cell, even under basal nonstimulatory conditions, must far exceed those normally bathing other tissues. This has to do with islet cell volume, limited interstitial space distribution, and constitutive rates of hormone output (16). Any attempt to establish either an inhibitory or excitatory effect of exogenous insulin on endogenous secretion must contend with this. For example, if insulin does indeed inhibit its own release as suggested in other reports (12, 14, 20), an inhibitory effect of added exogenous insulin on the secretory response to glucose might not be observed if saturating (with regards to insulin signaling) endogenous hormone concentrations already exist in the interstitial space and tonically influence secretion. In addition, it is technically difficult to measure endogenous insulin release rates in the presence of high levels of exogenously added hormone. In an attempt to circumvent these issues two approaches were utilized. First, we used C-peptide secretion rates as a surrogate marker for endogenous insulin secretion (37). Second, constitutive insulin signaling in the beta -cell was disrupted using inhibitors known to interfere with the kinases involved in the insulin signaling cascade.

Several salient points emerge from the present studies. First, C-peptide secretion rates accurately reflect both quantitatively and qualitatively the kinetics and amplitude of insulin secretion. Like insulin output in response to 10 mM glucose, it is biphasic in nature. Most importantly in terms of sensitivity, small increments in glucose-induced insulin release evoked by 7-8 mM glucose evoke small, easily measurable increments in C-peptide release. Third, in terms of inhibition of insulin secretion, we could not detect any inhibitory effect of exogenously added bovine insulin on glucose-induced insulin secretion. Fourth, neither bovine nor human insulin at levels of 100-500 nM had any discernible stimulatory effect on C-peptide secretion rates and, based on the tight coupling between C-peptide and insulin secretion demonstrated in these studies, exerted no stimulatory effect on insulin release as well. Fifth, addition of a membrane-active agonist, carbachol, evoked substantial insulin and C-peptide responses indicating that at least for this agonist the functional integrity of its membrane receptor has been maintained during the isolation procedures. However, because the insulin receptor may be more vulnerable to collagenase than the muscarinic cholinergic receptor, islets were allowed to recover from the isolation procedure during an 18-h culturing period. These islets still failed to respond to exogenously added insulin by increasing C-peptide secretion rates.

We were unable to document any inhibitory effect of exogenously added insulin on its own secretion using C-peptide as the surrogate marker for insulin release. Does this failure exclude an inhibitory effect of endogenously released insulin on the insulin release process? Does constitutive insulin secretion tonically influence stimulated secretion? We attempted to address this issue by using two different inhibitors known to disrupt the kinases involved in insulin signaling. Our findings with isolated perifused rat islets confirm the observations made using mouse islets (38) or neonatal cultured rat islets (39): genistein is a potentiator of glucose-induced secretion. Furthermore, our findings also confirm previous studies in both rat (23, 40) and mouse (41) islets as well as in MIN cells (42); wortmannin is a potentiator of glucose-induced secretion. Although it is known that these compounds may interfere with kinases not involved with insulin signaling and that these effects may complicate the interpretation of the data, the main point to be made is that these compounds significantly potentiated glucose-induced release. Whether or not these inhibitors act as we assume or influence other pathways (43) still makes these observations noteworthy and the pursuit of the precise underlying mechanisms involved an important goal for future studies. The findings also suggest that constitutive secretion may negatively affect stimulated secretion and that disruption of insulin signaling in the beta -cell improves glucose-stimulated insulin secretion.

Our working hypothesis is that constitutive insulin release from islets, even under nonstimulatory conditions, exerts a tonic inhibitory effect on stimulated secretion. The addition of exogenous insulin to a system already tonically inhibited has little further inhibitory effect as demonstrated here, but its disruption using several inhibitors markedly improves the secretory performance of the beta -cell. This hypothesis is consistent with findings made using knockout mice where insulin signaling has been disrupted and by pharmacologic inhibition of kinases thought to be involved in insulin signaling. For example, islets deficient in the insulin receptor substrate-2 protein or the p85alpha regulatory subunit of phosphatidylinositol 3-kinase hyper-respond to glucose stimulation (41, 44). Of particular physiologic significance, perhaps, is the observation that basal secretion is not augmented from these beta -cells. The impact of these genetic manipulations becomes manifest only in studies in which glucose stimulates release. This finding suggests that only under conditions in which insulin release is stimulated by glucose does insulin signaling negatively impact release. This situation is analogous to the alpha 2 adrenergic effects in the central nervous system where presynaptically released catecholamines feed back in a negative fashion on the cell that released it in order to restrain the secretion of additional neurotransmitter (45).

Our studies, as well as those of others, using pharmacologic inhibition of the kinase involved with insulin signaling are also consistent with the hypothesis that constitutive insulin signaling acts to restrain stimulated insulin secretion. For example, neither wortmannin nor genistein potentiates release from islets in the presence of low nonstimulatory glucose (23, 38). Their positive effect on secretion only becomes manifest when stimulatory glucose is employed. Although the specificity of these inhibitors on islet kinases remains to be determined, it has to be emphasized that these inhibitors reversibly potentiate glucose-induced insulin secretion, thus ruling out any untoward nonspecific toxic action. For wortmannin at least, and from a quantitative perspective, its potentiating effect is comparable with clinically utilized insulin secretagogues.

Recent interest in the potential role of insulin signaling on beta -cell response patterns has been generated largely as a result of studies in insulin signaling knockout animals (46-48). Amperometric measurements of 5HT release from normal or abnormal beta -cells have been used to support the concept that insulin stimulates its own secretion (6, 7). Our C-peptide measurements failed to reveal any stimulatory effect of exogenous insulin on C-peptide release, a surrogate marker of insulin secretion that accurately reflects small changes in the kinetics and amplitude of insulin release. The assay used to measure C-peptide secretion appears sensitive enough to measure small increments in insulin secretion. For example, the modest 4-5-fold increase in 8 mM glucose-induced release was paralleled by a modest 4-5-fold increase in C-peptide secretion. Even with 7 mM glucose alone, small but parallel 2-fold increments in both insulin and C-peptide release were recorded.

In conclusion, C-peptide release rates from perifused rat islets reflect accurately the kinetics and magnitude of glucose- and carbachol-induced insulin release. In perifused rat islets, exogenously added insulin has no inhibitory effect on endogenous insulin secretion monitored by C-peptide secretion rates. Exogenously added bovine or human insulin do not stimulate C-peptide release from islets and, by inference, also fail to exert any autocrine insulin stimulatory effect. Human insulin failed to affect C-peptide secretion from cultured islets as well. Known inhibitors of the kinases that participate in insulin signaling in other tissues significantly amplify glucose-induced secretion. Although the tonic impact of endogenously released insulin makes it technically difficult to establish an inhibitory effect of exogenously added hormone on the release process, any small autocrine stimulatory effect of added insulin, if it occurred, should have been readily detected considering the secretory capacity of the beta -cell and the sensitivity of the C-peptide assay. This was, however, not the case.

    ACKNOWLEDGEMENTS

We thank John Cassidy for helpful comments and suggestions.

    FOOTNOTES

* This work was supported by Grant 41230 from the NIDDK, National Institutes of Health and by the American Diabetes Association.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Yale University School of Nursing, P.O. Box 9740, 100 Church St. S., New Haven, CT 06536-0740. Tel.: 203-785-5522; Fax: 203-785-6455; E-mail: Walter.Zawalich@Yale.Edu.

Published, JBC Papers in Press, May 13, 2002, DOI 10.1074/jbc.M202291200

    ABBREVIATIONS

The abbreviations used are: 5HT, 5-hydroxytryptamine; C-peptide, connecting-peptide; PMA, phorbol 12-myristate 13-acetate.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Henquin, J. C., Bozem, M., Schmeer, W., and Nenquin, M. (1987) Biochem. J. 246, 393-399[Medline] [Order article via Infotrieve]
2. Malaisse, W. J., Sener, A., Herchuelz, A., and Hutton, J. C. (1979) Metabolism 28, 373-386[CrossRef][Medline] [Order article via Infotrieve]
3. Zawalich, W. S., and Zawalich, K. C. (1996) Am. J. Physiol. 271, E409-E416[Medline] [Order article via Infotrieve]
4. Ashcroft, S. J. (1980) Diabetologia 18, 5-15[CrossRef][Medline] [Order article via Infotrieve]
5. Best, L., and Malaisse, W. J. (1984) Endocrinology 115, 1820-1831[Free Full Text]
6. Aspinwall, C. A., Lakey, J. R. T., and Kennedy, R. T. (1999) J. Biol. Chem. 274, 6360-6365[Abstract/Free Full Text]
7. Aspinwall, C. A., Qian, W.-J., Roper, M. G., Kulkarni, R. N., Kahn, C. R., and Kennedy, R. T. (2000) J. Biol. Chem. 275, 22331-22338[Abstract/Free Full Text]
8. Lernmark, A. (1971) Horm. Metab. Res. 3, 305-309[Medline] [Order article via Infotrieve]
9. Gagliardino, J. J., Nierle, C., and Pfeiffer, E. F. (1974) Diabetologia 10, 411-414[CrossRef][Medline] [Order article via Infotrieve]
10. Zawalich, W. S., Tesz, G. J., and Zawalich, K. C. (2001) J. Biol. Chem. 276, 37120-37123[Abstract/Free Full Text]
11. Schatz, H., and Pfeiffer, E. F. (1977) J. Endocrinol. 74, 243-249[Abstract/Free Full Text]
12. Iversen, J., and Miles, D. W. (1971) Diabetes 20, 1-9[Medline] [Order article via Infotrieve]
13. Ammon, H. P., Reiber, C., and Verspohl, E. J. (1991) J. Endocrinol. 128, 27-34[Abstract/Free Full Text]
14. Loreti, L., Dunbar, J. C., Chen, S., and Foà, P. P. (1974) Diabetologia 10, 309-315[Medline] [Order article via Infotrieve]
15. Sodoyez, J.-C., Sodoyez-Goffaux, F., and Foà, P. P. (1969) Proc. Soc. Exp. Biol. Med. 130, 568-571[CrossRef][Medline] [Order article via Infotrieve]
16. Zawalich, W. S., Karl, R. C., Ferrendelli, J. A., and Matschinsky, F. M. (1975) Diabetologia 11, 231-235[CrossRef][Medline] [Order article via Infotrieve]
17. Verspohl, E. J., and Ammon, H. P. (1980) J. Clin. Invest. 65, 1230-1237[Medline] [Order article via Infotrieve]
18. Xu, G. G., and Rothenberg, P. L. (1998) Diabetes 47, 1243-1252[Abstract]
19. Harbeck, M. C., Louie, D. C., Howland, J., Wolf, B. A., and Rothenberg, P. L. (1996) Diabetes 45, 711-717[Abstract]
20. Ammon, H. P. T., and Verspohl, E. (1976) Endocrinology 99, 1469-1476[Abstract/Free Full Text]
21. Rappaport, A. M., Ohira, S., Coddling, J. A., Empey, G., Kalnins, A., Lin, B. J., and Haist, R. E. (1972) Endocrinology 91, 168-176[Abstract/Free Full Text]
22. Zawalich, W. S., and Zawalich, K. C. (2000) J. Endocrinol. 166, 111-120[Abstract]
23. Zawalich, W. S., and Zawalich, K. C. (2000) Endocrinology 141, 3287-3295[Abstract/Free Full Text]
24. Albano, J. D. M., Ekins, R. P., Maritz, G., and Turner, R. C. (1972) Acta Endocrinol. 70, 487-509[Medline] [Order article via Infotrieve]
25. Zawalich, W. S., Bonnet-Eymard, M., Zawalich, K. C., and Yaney, G. C. (1998) Am. J. Physiol. 274, C1388-C1396[Medline] [Order article via Infotrieve]
26. Zawalich, W. S., Zawalich, K. C., and Kelley, G. G. (1996) Eur. J. Physiol. 432, 589-596[CrossRef][Medline] [Order article via Infotrieve]
27. Gerich, J. E., Charles, M. A., and Grodsky, G. M. (1974) J. Clin. Invest. 54, 833-841[Medline] [Order article via Infotrieve]
28. Curry, D. L. (1986) Endocrinology 118, 170-175[Abstract/Free Full Text]
29. Grill, V., Adamson, U., and Cerasi, E. (1978) J. Clin. Invest. 61, 1034-1043[Medline] [Order article via Infotrieve]
30. Loubatieres-Mariani, M. M., Chapal, J., Alric, R., and Loubatieres, A. (1973) Diabetologia 9, 439-476[CrossRef][Medline] [Order article via Infotrieve]
31. Zawalich, W. S., Zawalich, K. C., and Rasmussen, H. (1989) Endocrinology 125, 2400-2406[Abstract/Free Full Text]
32. Kelley, G. G., Zawalich, K. C., and Zawalich, W. S. (1995) Am. J. Physiol. 269, E575-E582[Medline] [Order article via Infotrieve]
33. Malaisse-Lagae, F., Sener, A., and Malaisse, W. J. (1987) Acta Diabetol. Lat. 24, 17-25[Medline] [Order article via Infotrieve]
34. Metz, S. A. (1988) Diabetes 37, 3-7[Abstract]
35. Virkamäki, A., Ueki, K., and Kahn, C. R. (1999) J. Clin. Invest. 103, 931-943[Medline] [Order article via Infotrieve]
36. Pessin, E. J., and Saltiel, R. A. (2000) J. Clin. Invest. 106, 165-169[Medline] [Order article via Infotrieve]
37. Steiner, D. F. (1977) Diabetes 26, 322-340[Medline] [Order article via Infotrieve]
38. Jonas, J. C., Plant, T. D., Gilon, P., Detimary, P., Nenquin, M., and Henquin, J. C. (1995) Br. J. Pharmacol. 114, 872-880[Medline] [Order article via Infotrieve]
39. Sorenson, R. L., Brelje, T. C., and Roth, C. (1994) Endocrinology 134, 1975-1978[Abstract/Free Full Text]
40. Nunoi, K., Yasuda, K., Tanaka, H., Kubota, A., Okamoto, Y., Adachi, T., Shihara, N., Uno, M., Xu, L. M., Kagimoto, S., Seino, Y., Yamada, Y., and Tsuda, K. (2000) Biochem. Biophys. Res. Commun. 270, 798-805[CrossRef][Medline] [Order article via Infotrieve]
41. Eto, K., Yamashita, T., Tsubamoto, Y., Terauchi, Y., Hirose, K., Kubota, N., Yamahita, S., Taka, J., Satoh, S., Sekihara, H., Tobe, K., Iino, M., Noda, M., Kimura, S., and Kadowaki, T. (2002) Diabetes 51, 87-97[Abstract/Free Full Text]
42. Hagiwara, S., Sakurai, T., Tashiro, F., Hashimoto, Y., Matsuda, Y., Nonomura, Y., and Miyazaki, J. (1995) Biochem. Biophys. Res. Commun. 214, 51-59[CrossRef][Medline] [Order article via Infotrieve]
43. Leahy, J. L., and Vandekerkhove, K. M. (1990) Endocrinology 126, 1593-1598[Abstract/Free Full Text]
44. Kubota, N., Tobe, K., Terauchi, Y., Eto, K., Yamauchi, T., Suzuki, R., Tsubamoto, Y., Komeda, K., Nakano, R., Miki, H., Satoh, S., Sekihara, H., Sciacchitano, S., Lesniak, M., Aizawa, S., Nagai, R., Kimura, S., Akanuma, Y., Taylor, S. I., and Kadowaki, T. (2000) Diabetes 49, 1880-1889[Abstract]
45. Langer, S. Z. (1981) Pharmacol. Rev. 32, 337-362
46. Kulkarni, R. N., Bruning, J. C., Winnay, J. N., Postic, C., Magnuson, M. A., and Kahn, C. R. (1999) Cell 96, 329-339[CrossRef][Medline] [Order article via Infotrieve]
47. Kulkarni, R. N., Winnay, J. N., Daniels, M., Brüning, J. C., Flier, S. N., Hanahan, D., and Kahn, C. R. (1999) J. Clin. Invest. 104, R69-R75[Medline] [Order article via Infotrieve]
48. Eto, K., Tsubamoto, Y., Terauchi, Y., Waki, K., Kubota, N., Taka, J., Tamemoto, H., Tobe, K., Noda, M., and Kadowaki, T. (2000) Diabetes 49, (A45)


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. K. Lingohr, I. Briaud, L. M. Dickson, J. F. McCuaig, C. Alarcon, B. L. Wicksteed, and C. J. Rhodes
Specific Regulation of IRS-2 Expression by Glucose in Rat Primary Pancreatic Islet beta-Cells
J. Biol. Chem., June 9, 2006; 281(23): 15884 - 15892.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. I. Borelli, F. Francini, and J. J. Gagliardino
Autocrine regulation of glucose metabolism in pancreatic islets
Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E111 - E115.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
B. Wicksteed, C. Alarcon, I. Briaud, M. K. Lingohr, and C. J. Rhodes
Glucose-induced Translational Control of Proinsulin Biosynthesis Is Proportional to Preproinsulin mRNA Levels in Islet {beta}-Cells but Not Regulated via a Positive Feedback of Secreted Insulin
J. Biol. Chem., October 24, 2003; 278(43): 42080 - 42090.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S. Srivastava and H. J. Goren
Insulin Constitutively Secreted by {beta}-Cells Is Necessary for Glucose-Stimulated Insulin Secretion
Diabetes, August 1, 2003; 52(8): 2049 - 2056.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
I. Briaud, M. K. Lingohr, L. M. Dickson, C. E. Wrede, and C. J. Rhodes
Differential Activation Mechanisms of Erk-1/2 and p70S6K by Glucose in Pancreatic {beta}-Cells
Diabetes, April 1, 2003; 52(4): 974 - 983.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
M. E. Doyle and J. M. Egan
Pharmacological Agents That Directly Modulate Insulin Secretion
Pharmacol. Rev., March 1, 2003; 55(1): 105 - 131.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/29/26233    most recent
M202291200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zawalich, W. S.
Right arrow Articles by Zawalich, K. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zawalich, W. S.
Right arrow Articles by Zawalich, K. C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement